Checkpoint Therapeutics

As temperatures rise, it is essential to balance the benefits of Vitamin D with proper sun protection. While Vitamin D plays a crucial role in overall health, excessive sun exposure can increase the risk of skin damage. For more information, visit the American Cancer Society’s page on key Vitamin D facts:

Sun Safety and Vitamin D Your skin makes vitamin D naturally when it is exposed to UV rays, but it's still important to protect your skin. Learn how you can get vitamin D while still staying safe in the sun.

Planning a spring break getaway? Remember to protect your skin by choosing the right sunscreen. The American Academy of Dermatology provides expert answers to frequently asked questions on selecting the most effective sunscreen, proper application timing and how to maximize sun protection. Learn more:

Sunscreen FAQs Dermatologists recommend using sunscreen with SPF 30+ that is broad-spectrum and water resistant.

While navigating skin concerns can be intimidating, know that you are not alone. Whether you're seeking a second opinion or specialized care, finding the right dermatologist for your needs is important. The American Academy of Dermatology offers guidance on selecting the best provider for you:

How to select a dermatologist You have choices when it comes to your health care. Here’s how to choose the dermatologist who aligns with your needs.

This Black History Month, Checkpoint Therapeutics wants to remind you that while individuals with darker skin tones have a lower risk of skin cancer, it can still occur. Regular skin self-exams and sun protection are essential for everyone, regardless of skin color. The American Cancer Society offers tips on protecting your skin year-round. Learn more:

What People of Color Need to Know About Sun Protection and Skin Cancer People with darker skin need protection from the sun’s harmful UV rays that can cause sunburn and skin cancer. Find out the signs and symptoms of skin cancer.

This World Cancer Day, Checkpoint Therapeutics encourages you to protect your skin and stay vigilant through regular self-skin exams and professional screenings to detect skin cancer—one of the most common types of cancer. Remember, prevention and detection save lives. Learn more about the warning signs to watch for today and every day: https://www.aad.org/public/diseases/skin-cancer/prevent/how

ICYMI: Medscape reporter Worcester highlighted the FDA approval of Checkpoint’s UNLOXCYT (cosibelimab-ipdl), and how it can benefit individuals with advanced cutaneous squamous cell carcinoma (cSCC) who are not suitable candidates for surgery or radiation therapy. Read the full article here: https://www.medscape.com/viewarticle/fda-approves-cosibelimab-cutaneous-scc-2024a1000n94?reg=1

Did you know that snow acts like a mirror, doubling your UV exposure by bouncing the sun’s rays back at you? Whether you're skiing, snowboarding, or simply shoveling the driveway this winter season, Checkpoint reminds you to prioritize sun safety as part of your daily routine. Check out the The American Academy of Dermatology winter skin survival kit for tips on staying protected:

Your winter skin survival kit As temperatures dip, here are some products that can help your skin look and feel its best throughout the colder months.

Find detailed information about UNLOXCYT (cosibelimab-ipdl) on our new landing page! Visit www.unloxcyt.com to learn more.

Thank you to Endpoints reporter Lei Lei Wu for highlighting our recent FDA approval and how this news marks our first marketing approval, transitioning Checkpoint into a commercial-stage entity. Read the full article here: https://endpts.com/checkpoint-wins-fda-approval-of-checkpoint-inhibitor-in-advanced-skin-cancer-seeks-partner-for-launch/

Happy Holidays! Checkpoint wishes you and your family a wonderful holiday season and a Happy New Year!

In case you missed it: Checkpoint Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted approval for UNLOXCYT, a treatment for adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are ineligible for curative surgery or radiation. Read below for insights from James Oliviero, President and Chief Executive Officer of Checkpoint, on this significant milestone.

Today, the U.S. Food and Drug Administration has approved UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (“PD-L1”) blocking antibody to receive FDA marketing approval for this indication. Details in the press release here:

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) December 13, 2024 6:15pm EST Download as PDF UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint T...